Breast Cancer

Detailed Overview

Breast cancer typically presents as an asymptomatic lump discovered on screening mammography or via clinical breast exam. The two most common histologic types are Invasive Ductal Carcinoma (IDC, ~80%) and Invasive Lobular Carcinoma (ILC, ~10%). Treatment requires a multidisciplinary approach involving surgery (lumpectomy or mastectomy), radiation, and systemic therapies. Systemic therapy is tailored to the tumor subtype: endocrine therapy for hormone receptor-positive tumors, HER2-targeted therapy for HER2-amplified tumors, and cytotoxic chemotherapy for triple-negative or high-risk disease. Early detection drastically improves survival rates.

Epidemiology & Demographics

It is the most frequently diagnosed cancer in women worldwide. In the US, a woman's lifetime risk of developing breast cancer is roughly 1 in 8 (13%). Median age at diagnosis is 62 years. It is rare in men, representing less than 1% of all breast cancer cases.

Etiological Mechanism

Arises from genetic mutations in breast epithelial cells, accumulated through a combination of aging, environmental exposures (especially lifetime estrogen exposure), and inherited genetic susceptibility.

Primary Causes

Most cases are sporadic. About 5-10% of cases are strictly hereditary, most commonly due to autosomal dominant mutations in the BRCA1 and BRCA2 tumor suppressor genes.

• Age and Gender: Risk increases significantly with advancing age; female sex is the primary risk factor.
• Prolonged Estrogen Exposure: Early menarche (<12 years), late menopause (>55 years), nulliparity, or older age at first live birth (>30 years).
• Genetic Mutations: BRCA1, BRCA2, PALB2, or PTEN mutations confer a drastically higher lifetime risk.
• Hormone Replacement Therapy (HRT): Use of combined estrogen and progestin therapy post-menopause increases risk.
• High Breast Density: More glandular tissue compared to fatty tissue increases risk and makes mammographic detection harder.

Normal breast epithelial cells undergo transformation due to genetic and epigenetic alterations. Overexpression of estrogen receptors (ER) drives cell proliferation via estrogen signaling. Amplification of the ERBB2 gene leads to overexpression of the HER2 transmembrane tyrosine kinase receptor, promoting aggressive cell division and survival. The transformation begins as atypical hyperplasia, progresses to carcinoma in situ (ductal or lobular, confined by the basement membrane), and eventually breaches the basement membrane to become invasive carcinoma. From the local stroma, cancer cells invade lymphatic channels, spreading first to the axillary lymph nodes, and hematogenously to distant organs (bone, liver, lung, brain).

Characteristic Clinical Presentation

• Painless Breast Mass: A hard, immobile, irregularly bordered lump is the most common presenting symptom.
• Nipple Discharge: Unilateral, spontaneous bloody or clear discharge.
• Skin Changes: Skin dimpling, retraction, or Peau d'orange (thickened skin with prominent pores mimicking an orange peel).
• Nipple Retraction: Newly inverted or pulled-in nipple.

Physical Examination Signs

• Palpable, firm, fixed mass in the breast (often upper outer quadrant)
• Palpable axillary or supraclavicular lymphadenopathy
• Skin tethering or ulceration
• Erythema and edema of the breast (hallmark of inflammatory breast cancer)

• Metastasis: Spread to vital organs leading to organ failure and death.
• Lymphedema: Chronic swelling of the arm following axillary lymph node dissection and radiation.
• Pathologic Fractures: Bone metastases causing severe pain, hypercalcemia, and structural failure of bones.
• Treatment Toxicities: Cardiotoxicity (Trastuzumab, Anthracyclines), neuropathy (Taxanes), and early menopause.

Diagnostic Criteria & Guidelines

Diagnosis is confirmed by a core needle biopsy of the suspicious lesion showing malignant cells. The tissue MUST be tested for Estrogen Receptor (ER), Progesterone Receptor (PR), and HER2 status to guide therapy.

Differential Diagnosis

• Fibroadenoma
• Fibrocystic Breast Changes
• Mastitis or Breast Abscess
• Fat Necrosis (often post-trauma)
• Intraductal Papilloma

Laboratory Tests & Biomarkers

• Receptor Testing (IHC/FISH): Determines HR+, HR-, HER2+, or HER2- status. E.g., ER strongly positive (>10% cells).
• Genomic Assays (e.g., Oncotype DX): Tests early-stage HR+ tumors to predict the benefit of adding chemotherapy; a low score indicates endocrine therapy alone is sufficient.
• BRCA Gene Testing: Blood test indicating pathogenic mutation in BRCA1/2, guiding surgical and PARP inhibitor decisions.

Imaging Modalities & Findings

• Diagnostic Mammogram:
• Breast Ultrasound:
• Breast MRI:

• Stage 0
  Carcinoma in situ (DCIS or LCIS); abnormal cells have not invaded nearby stroma.
• Stage I/II
  Early-stage invasive cancer, relatively small tumor, with or without limited spread to axillary nodes.
• Stage III
  Locally advanced cancer, larger tumor size, extensive axillary node involvement, or skin/chest wall involvement.
• Stage IV
  Metastatic breast cancer; spread to distant organs such as bones, liver, lungs, or brain.

Second-Line & Adjunctive Therapy

For metastatic or recurrent disease: Systemic therapy is primary. HR+/HER2-: CDK4/6 inhibitors (Palbociclib 125 mg/day) + Endocrine therapy. HER2+: Trastuzumab deruxtecan (Enhertu) or Tucatinib regimens. TNBC: Immunotherapy (Pembrolizumab) + Chemotherapy, or Sacituzumab govitecan. BRCA-mutated: PARP inhibitors (Olaparib 300 mg BID).

Surgical & Procedural Management

Mastectomy (removal of the entire breast) is indicated for multicentric disease, large tumor-to-breast ratio, prior breast radiation, or patient preference. Axillary clearance is required if sentinel lymph nodes are heavily involved.

Recommended Lifestyle Changes

• Maintain a healthy body weight, as adipose tissue produces estrogen post-menopause.
• Limit alcohol intake, as it is a known risk factor.
• Engage in regular cardiovascular exercise (at least 150 minutes/week).

Patient Counseling & Advice

Educate the patient on the side effects of endocrine therapy, such as hot flashes, arthralgias, and vaginal dryness. Emphasize that completing the full 5-10 year course of anti-estrogen pills is critical for preventing late recurrences. Discuss fertility preservation options before starting chemotherapy in young women.

Follow-Up & Monitoring Schedule

History and physical exam every 3-6 months for the first 3 years, then every 6-12 months for years 4-5, then annually. Annual screening mammography of the remaining breast tissue.

Preventive Strategies

Screening: Annual mammography starting at age 40 for average-risk women. High-risk women (BRCA+) require MRI screening starting at age 25. Chemoprevention: Tamoxifen or Raloxifene for 5 years can reduce risk in women with high-risk lesions (e.g., LCIS). Prophylactic bilateral mastectomy and salpingo-oophorectomy significantly reduce risk in BRCA carriers.

Highly dependent on stage and subtype. The 5-year relative survival rate for localized breast cancer is 99%. For regional (node-positive) disease, it is 86%. For metastatic disease, it is 30%. TNBC historically has the worst prognosis among subtypes.